A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases

Ceelen, Wim
Sandra, Louis
Van de Sande, Leen
Graversen, M
Mortensen, MB
Vermeulen, An
Gasthuys, Elke
Reynders, Dries
Cosyns, Sarah
Hoorens, Anne
Willaert, Wouter

January 2022

Background Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel method to treat p...

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

De Clercq, Kaat
Xie, Feifan
De Wever, Olivier
Descamps, Benedicte
Hoorens, Anne
Vermeulen, An
Ceelen, Wim
Vervaet, Chris

January 2019

Patients with advanced ovarian cancer develop recurrence despite initial treatment response to stand...

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

Rose, Peter G.
Blessing, John A.
Ball, Harrison G., III
Hoffman, James
Warshal, David
DeGeest, Koen
Moore, David H.

February 2003

OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity ...

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Coleman, Robert L.
Brady, William E.
McMeekin, D. Scott
Rose, Peter G.
Soper, John T.
Lentz, Samuel S.
Hoffman, James S.
Shahin, Mark S.

January 2011

Nab-paclitaxel is a novel Cremophor®-free nanoparticle of albumin-stabilized paclitaxel, which has f...

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer. Clinical results and biological observations in taxane-pretreated patients

Fabi A.
Giannarelli D.
Malaguti P.
Ferretti G.
Vari S.
Papaldo P.
Nistico C.
Caterino M.
DE VITA, Roy
Mottolese Marcella.
IACOROSSI, laura
Cognetti F.

January 2015

Background: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, sin...

A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies

Williamson, Stephen K.
Johnson, Gary A.
Maulhardt, Holly A.
Moore, Kathleen M.
McMeekin, D. S.
Schulz, Thomas K.
Reed, Gregory A.
Roby, Katherine F.
Mackay, Christine B.
Smith, Holly J.
Weir, Scott J.
Wick, Jo A.
Markman, Maurie
diZerega, Gere S.
Baltezor, Michael J.
Espinosa, Jahna
Decedue, Charles J.

May 2015

PURPOSE: This multicenter, open-label, dose-escalating, phase I study evaluated the safety, tolerabi...

Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab (R)-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma

Huang, Yan
Liang, Wenhua
Yang, Yunpeng
Zhao, Liping
Zhao, Hongyun
Wu, Xuan
Zhao, Yuanyuan
Zhang, Yang
Zhang, Li

January 2016

Background: This phase I/II study aimed to determine the maximum tolerated dose (MTD) of nanoparticl...

Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies

Stinchcombe, Thomas E.
Socinski, Mark A.
Lee, Carrie B.
Hayes, D Neil
Moore, Dominic T.
Goldberg, Richard M.
Dees, E Claire

January 2008

Nab-paclitaxel has a different toxicity profile than solvent-based paclitaxel including a lower rate...

A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study

Burton, Elizabeth R.
Brady, Mark
Homesley, Howard D.
Rose, Peter G.
Nakamura, Toshiaki
Kesterson, Joshua P.
Rotmensch, Jacob
Tate Thigpen,
Van Le, Linda

January 2016

To estimate the probability of complete clinical response and toxicity of paclitaxel as second-line ...

Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer

Nuhad K. Ibrahim
Brian Samuels
Dinesh Doval
Kirtikumar M. Patel
S. C. Rao
Madhavan Krishnan Nair
Paul Bhar
Neil Desai
Gabriel N. Hortobagyi

January 2005

ABI-007 is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. This multicenter...

Albumin-Bound Paclitaxel in the Treatment of Metastatic Breast Cancer

Alicia Soria Lovelle
Miguel Martín
Medical Oncology Service
Hospital Universitario
Gregorio Marañón

November 2015

Abstract: The taxanes, paclitaxel and docetaxel, are an important class of antineoplastic agents wit...

Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.

VERGARA, DANIELE
RINALDI, Rosaria
MAFFIA, Michele
C. BELLOMO
X. ZHANG
VERGARO, VIVIANA
A. TINELLI
V. LORUSSO
Y. M. LVOV
S. LEPORATTI

January 2012

The sonication-assisted layer-by-layer (SLBL) technology was developed to combine necessary factors ...

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)

Rugo, Hope S.
Barry, William T.
Moreno-Aspitia, Alvaro
Lyss, Alan P.
Cirrincione, Constance
Leung, Eleanor
Mayer, Erica L.
Naughton, Michael
Toppmeyer, Deborah
Carey, Lisa A.
Perez, Edith A.
Hudis, Clifford
Winer, Eric P.
mprehensive Cancer Center, San Francisco, CA

January 2015

We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line...

Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: Prospective evaluation of activity, safety, and quality of life

Palumbo R.
Sottotetti F.
Trifiro G.
Piazza E.
Ferzi A.
Gambaro A.
Spinapolice E. G.
Pozzi E.
Tagliaferri B.
Teragni C.
Bernardo A.

January 2015

Background: A prospective, multicenter trial was undertaken to assess the activity, safety, and qual...

A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer

Grilley-Olson, J. E.
Keedy, V. L.
Sandler, A.
Moore, D. T.
Socinski, M. A.
Stinchcombe, T. E.

January 2015

Platinum plus etoposide is the standard therapy for extensive-stage small cell lung cancer (ES-SCLC)...

Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases

Ceelen, Wim
Sandra, Louis
Van de Sande, Leen
Graversen, M
Mortensen, MB
Vermeulen, An
Gasthuys, Elke
Reynders, Dries
Cosyns, Sarah
Hoorens, Anne
Willaert, Wouter

January 2022

Background Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel method to treat p...

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

De Clercq, Kaat
Xie, Feifan
De Wever, Olivier
Descamps, Benedicte
Hoorens, Anne
Vermeulen, An
Ceelen, Wim
Vervaet, Chris

January 2019

Patients with advanced ovarian cancer develop recurrence despite initial treatment response to stand...

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

Rose, Peter G.
Blessing, John A.
Ball, Harrison G., III
Hoffman, James
Warshal, David
DeGeest, Koen
Moore, David H.

February 2003

OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity ...

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Coleman, Robert L.
Brady, William E.
McMeekin, D. Scott
Rose, Peter G.
Soper, John T.
Lentz, Samuel S.
Hoffman, James S.
Shahin, Mark S.

January 2011

Nab-paclitaxel is a novel Cremophor®-free nanoparticle of albumin-stabilized paclitaxel, which has f...

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer. Clinical results and biological observations in taxane-pretreated patients

Fabi A.
Giannarelli D.
Malaguti P.
Ferretti G.
Vari S.
Papaldo P.
Nistico C.
Caterino M.
DE VITA, Roy
Mottolese Marcella.
IACOROSSI, laura
Cognetti F.

January 2015

Background: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, sin...

A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies

Williamson, Stephen K.
Johnson, Gary A.
Maulhardt, Holly A.
Moore, Kathleen M.
McMeekin, D. S.
Schulz, Thomas K.
Reed, Gregory A.
Roby, Katherine F.
Mackay, Christine B.
Smith, Holly J.
Weir, Scott J.
Wick, Jo A.
Markman, Maurie
diZerega, Gere S.
Baltezor, Michael J.
Espinosa, Jahna
Decedue, Charles J.

May 2015

PURPOSE: This multicenter, open-label, dose-escalating, phase I study evaluated the safety, tolerabi...

Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab (R)-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma

Huang, Yan
Liang, Wenhua
Yang, Yunpeng
Zhao, Liping
Zhao, Hongyun
Wu, Xuan
Zhao, Yuanyuan
Zhang, Yang
Zhang, Li

January 2016

Background: This phase I/II study aimed to determine the maximum tolerated dose (MTD) of nanoparticl...

Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies

Stinchcombe, Thomas E.
Socinski, Mark A.
Lee, Carrie B.
Hayes, D Neil
Moore, Dominic T.
Goldberg, Richard M.
Dees, E Claire

January 2008

Nab-paclitaxel has a different toxicity profile than solvent-based paclitaxel including a lower rate...

A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study

Burton, Elizabeth R.
Brady, Mark
Homesley, Howard D.
Rose, Peter G.
Nakamura, Toshiaki
Kesterson, Joshua P.
Rotmensch, Jacob
Tate Thigpen,
Van Le, Linda

January 2016

To estimate the probability of complete clinical response and toxicity of paclitaxel as second-line ...

Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer

Nuhad K. Ibrahim
Brian Samuels
Dinesh Doval
Kirtikumar M. Patel
S. C. Rao
Madhavan Krishnan Nair
Paul Bhar
Neil Desai
Gabriel N. Hortobagyi

January 2005

ABI-007 is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. This multicenter...

Albumin-Bound Paclitaxel in the Treatment of Metastatic Breast Cancer

Alicia Soria Lovelle
Miguel Martín
Medical Oncology Service
Hospital Universitario
Gregorio Marañón

November 2015

Abstract: The taxanes, paclitaxel and docetaxel, are an important class of antineoplastic agents wit...

Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.

VERGARA, DANIELE
RINALDI, Rosaria
MAFFIA, Michele
C. BELLOMO
X. ZHANG
VERGARO, VIVIANA
A. TINELLI
V. LORUSSO
Y. M. LVOV
S. LEPORATTI

January 2012

The sonication-assisted layer-by-layer (SLBL) technology was developed to combine necessary factors ...

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)

Rugo, Hope S.
Barry, William T.
Moreno-Aspitia, Alvaro
Lyss, Alan P.
Cirrincione, Constance
Leung, Eleanor
Mayer, Erica L.
Naughton, Michael
Toppmeyer, Deborah
Carey, Lisa A.
Perez, Edith A.
Hudis, Clifford
Winer, Eric P.
mprehensive Cancer Center, San Francisco, CA

January 2015

We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line...

Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: Prospective evaluation of activity, safety, and quality of life

Palumbo R.
Sottotetti F.
Trifiro G.
Piazza E.
Ferzi A.
Gambaro A.
Spinapolice E. G.
Pozzi E.
Tagliaferri B.
Teragni C.
Bernardo A.

January 2015

Background: A prospective, multicenter trial was undertaken to assess the activity, safety, and qual...

A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer

Grilley-Olson, J. E.
Keedy, V. L.
Sandler, A.
Moore, D. T.
Socinski, M. A.
Stinchcombe, T. E.

January 2015

Platinum plus etoposide is the standard therapy for extensive-stage small cell lung cancer (ES-SCLC)...

Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases

Ceelen, Wim
Sandra, Louis
Van de Sande, Leen
Graversen, M
Mortensen, MB
Vermeulen, An
Gasthuys, Elke
Reynders, Dries
Cosyns, Sarah
Hoorens, Anne
Willaert, Wouter

January 2022

Background Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel method to treat p...

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

De Clercq, Kaat
Xie, Feifan
De Wever, Olivier
Descamps, Benedicte
Hoorens, Anne
Vermeulen, An
Ceelen, Wim
Vervaet, Chris

January 2019

Patients with advanced ovarian cancer develop recurrence despite initial treatment response to stand...

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

Rose, Peter G.
Blessing, John A.
Ball, Harrison G., III
Hoffman, James
Warshal, David
DeGeest, Koen
Moore, David H.

February 2003

OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity ...

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Abstract

Extracted data

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Abstract

Extracted data

Related items

Related items